



# ENGOT-OV24-NSGO / AVANOVA part 3 Sponsor: NSGO

**Stratification factors:**  
HRD positive/negative  
TFI: 6-12 mo vs. >12 mo



Randomization: 1:1  
**n=94**  
Hypothesis: Arm 1: niraparib median PFS 8mdr  
Arm2: Nir + Bev median PFS 14mdr  
HR 0.57  
Power 80%  
alpha 0.1  
inclusion 18 months



TR blood tests: day 0 + 14 + 28. 42 + 56 + 84 + at PD)

Biopsy day 0 + d 84 + at PD)

---

**Same Inclusion / exclusion criteria**

**Same sites**

**Number of BRCAmut patients capped to the same ratio as in part 2**

### **Trial status:**

**PART 1** (*phase 1; niraparib-bevacizumab; 12 patients*)

Manuscript being prepared

**PART 2** (*phase 2 randomized; niraparib-bevacizumab versus niraparib; 103 patients*)

Events maturity awaited

**PART 3** (*phase 2 triplet; niraparib-bevacizumab-TSR042; 72 patients*)

To be started in Q1